Lineage Cell Therapeutics (LCTX) Tax Rate (2014 - 2023)

Lineage Cell Therapeutics (LCTX) posted quarterly Tax Rate of 29.05% for Q1 2023, up 4407.38% quarter-over-quarter from 0.64% in Q4 2022.

Lineage Cell Therapeutics (LCTX) Tax Rate (2014 - 2023) Analysis & Trends

Lineage Cell Therapeutics' Tax Rate history runs 5 years deep, the most recent figure standing at 29.05% for Q1 2023.

In Q1 2023, Tax Rate changed N/A year-over-year to 29.05%; the TTM figure through Dec 2023 stood at 7.74% (down 4866.0% YoY), while the FY2025 annual figure was 7.69%, changed N/A from the prior year.
Tax Rate for Q1 2023 stood at 29.05%, up from 0.64% in the prior quarter.
The five-year high for Tax Rate was 262.3% in Q4 2019, with the low at 8.97% in Q3 2022.
The 4-year median for Tax Rate is 6.04% (2021), against an average of 37.18%.
Peak annual rise in Tax Rate reached 2041 bps in 2022, while the deepest fall reached 2041 bps in 2022.
Lineage Cell Therapeutics' Tax Rate stood at 262.3% in 2019, then plunged by 96 bps to 11.44% in 2021, then slumped by 94 bps to 0.64% in 2022, then soared by 4407 bps to 29.05% in 2023.
Business Quant data shows LCTX's Tax Rate at 29.05% in Q1 2023, 0.64% in Q4 2022, and 8.97% in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Tax Rate (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	20.98%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	15.11%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	10.91%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	24.15%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-9.47%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	7.49%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-16.71%
10	Lineage Cell Therapeutics	270.61 Mn	212.77 Mn	1.07 Mn	-

Download Data